Emergent BioSolutions (EBS) Gross Profit Growth (3y) (2014 - 2026)
Emergent BioSolutions (EBS) Gross Profit Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 7.62% |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn | 4.71% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | -7.64% |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 12.55% |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - | - |
| 7 | Viatris | 20.23 Bn | 18.42 Bn | 1.16 Bn | -9.13% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 24.80% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 0.95% |
| 10 | Emergent BioSolutions | 383.02 Mn | 221.52 Mn | 84.10 Mn | 94.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.67% |
| Dec 31, 2025 | -26.84% |
| Sep 30, 2025 | 16.13% |
| Jun 30, 2025 | -23.11% |
| Mar 31, 2025 | -15.87% |
| Dec 31, 2024 | -52.84% |
| Sep 30, 2024 | -11.80% |
| Mar 31, 2024 | -21.69% |
| Dec 31, 2023 | -7.09% |
| Sep 30, 2023 | -35.94% |
| Jun 30, 2023 | -17.77% |
| Mar 31, 2023 | -53.80% |
| Dec 31, 2022 | -17.38% |
| Sep 30, 2022 | -23.09% |
| Jun 30, 2022 | 4.56% |
| Mar 31, 2022 | 31.47% |
| Dec 31, 2021 | 66.92% |
| Sep 30, 2021 | 33.70% |
| Jun 30, 2021 | 29.95% |
| Mar 31, 2021 | 72.23% |